Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference-Reference-Cited by-同舟云学术

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference

Published:2023-04 Issue:4 Volume:24 Page:e161-e171
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rahman Rifaquat,Polley Mei-Yin C,Alder Laura,Brastianos Priscilla K,Anders Carey K,Tawbi Hussein A,Mehta Minesh,Wen Patrick Y,Geyer Susan,de Groot John,Zadeh Gelareh,Piantadosi Steven,Galanis Evanthia,Khasraw Mustafa

Publisher

Elsevier BV

Subject

Oncology

Reference84 articles.

1. Management of glioblastoma: state of the art and future directions;Tan;CA Cancer J Clin,2020

2. The evolving modern management of brain metastasis;Fecci;Clin Cancer Res,2019

3. Designing clinical trials for combination immunotherapy: a framework for glioblastoma;Singh;Clin Cancer Res,2022

4. Glioblastoma clinical trials: current landscape and opportunities for improvement;Bagley;Clin Cancer Res,2022

5. The blood-tumour barrier in cancer biology and therapy;Steeg;Nat Rev Clin Oncol,2021

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A biomimetic targeted nanosystem delivering synergistic inhibitors for glioblastoma immune microenvironment reprogramming and treatment;Materials Today Bio;2024-10

2. Update on the intriguing roles of AQP4 expression and redistribution in the progression and treatment of glioma;Annals of Medicine;2024-09-09

3. Neurological insights into brain-targeted cancer therapy and bioinspired microrobots;Drug Discovery Today;2024-09

4. Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT;Clinical Cancer Research;2024-06-05

5. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology;Neuro-Oncology;2024-03-22